Literature DB >> 1381860

Histochemical study of pituitary adenomas with Ki-67 and anti-DNA polymerase alpha monoclonal antibodies, bromodeoxyuridine labeling, and nucleolar organizer region counts.

M Shibuya1, F Saito, T Miwa, R L Davis, C B Wilson, T Hoshino.   

Abstract

The growth potential of 65 pituitary adenomas was determined by histochemical analysis with Ki-67 and anti-DNA polymerase alpha monoclonal antibodies, bromodeoxyuridine (BrdUdR) labeling, and counts of argyrophilic nucleolar organizer regions (Ag-NORs). The mean proliferating cell indices (PCIs) determined by Ki-67 and anti-DNA polymerase alpha and the BrdUdR labeling index (LI) were generally very low [1.0 +/- 0.2%, 1.1 +/- 0.2%, and 0.5 +/- 0.1% (+/- SE), respectively]. Apart from adrenocorticotropic hormone-positive adenomas, which had significantly higher indices, there were no statistically significant differences in the indices among the other subtypes of pituitary adenomas. Recurrent tumors had higher Ki-67 and DNA polymerase alpha PCIs and BrdUdR LIs (3.6%, 4.2%, 1.4%) than primary tumors (0.8%, 0.8%, 0.3%; P less than 0.005). The number of Ag-NORs did not correlate significantly with any of the three indices. The mean number of Ag-NORs was higher in nonfunctioning adenomas than in functioning adenomas (2.04 vs 1.66, P less than 0.005); among prolactin-positive adenomas, those treated preoperatively with bromocriptine had more Ag-NORs than untreated tumors (1.75 vs 1.57, P less than 0.005). These results suggest that the Ki-67 and DNA polymerase alpha PCIs and the BrdUdR LI predict the growth potential of individual pituitary adenomas, whereas the number of Ag-NORs appears to correlate with hormone production rather than with the proliferative potential.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381860     DOI: 10.1007/bf00311392

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  33 in total

1.  Embedding and fixation techniques for immunohistochemical staining with anti-DNA polymerase alpha and Ki-67 monoclonal antibodies to analyze the proliferative potential of tumors.

Authors:  M Shibuya; T Miwa; T Hoshino
Journal:  Biotech Histochem       Date:  1992-05       Impact factor: 1.718

2.  Meningiomas: clinical implications of a high proliferative potential determined by bromodeoxyuridine labeling.

Authors:  M Shibuya; T Hoshino; S Ito; M R Wacker; M D Prados; R L Davis; C B Wilson
Journal:  Neurosurgery       Date:  1992-04       Impact factor: 4.654

3.  Radiotherapy in the treatment of pituitary adenomas.

Authors:  M Chun; G B Masko; S Hetelekidis
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-08       Impact factor: 7.038

4.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

5.  Argyrophil organizer region proteins (AgNORs) in adenohypophysial cells and adenomas of the human pituitary.

Authors:  L Stefaneanu; E Horvath; K Kovacs
Journal:  Mod Pathol       Date:  1989-05       Impact factor: 7.842

6.  Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67.

Authors:  E Knosp; K Kitz; A Perneczky
Journal:  Neurosurgery       Date:  1989-12       Impact factor: 4.654

7.  Immunological determination of labeling index on human tumor tissue sections using monoclonal anti-BrdUrd antibody.

Authors:  K Sasaki; T Ogino; M Takahashi
Journal:  Stain Technol       Date:  1986-05

8.  Nucleolar organizer regions in meningioma.

Authors:  T Orita; K Kajiwara; T Nishizaki; N Ikeda; T Kamiryo; H Aoki
Journal:  Neurosurgery       Date:  1990-01       Impact factor: 4.654

9.  Prolactin cell carcinoma of the pituitary. Clinicopathologic, immunohistochemical, and ultrastructural study of a case with cranial and extracranial metastases.

Authors:  B W Scheithauer; R V Randall; E R Laws; K T Kovacs; E Horvath; M D Whitaker
Journal:  Cancer       Date:  1985-02-01       Impact factor: 6.860

10.  Immunohistochemical demonstration of DNA polymerase alpha in human brain-tumor cells.

Authors:  K Kunishio; N Mishima; T Matsuhisa; K Tsuno; N Matsumi; T Satoh; K Matsumoto; T Furuta; A Nishimoto; T Shiraishi
Journal:  J Neurosurg       Date:  1990-02       Impact factor: 5.115

View more
  22 in total

1.  Abstracts of the 8th International Pituitary Pathology Meeting. October 5-9, 2001. Greece.

Authors: 
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

2.  Determination of cell proliferation using Mcm2 antigen and evaluation of apoptosis and TGF-beta1 expression in GH-secreting or clinically nonfunctioning pituitary adenomas.

Authors:  Cristina Micheletto Dallago; Ligia Maria Barbosa-Coutinho; Nelson Pires Ferreira; Rosalva Meurer; Julia Fernanda Semmelmann Pereira-Lima; Miriam da Costa Oliveira
Journal:  Endocr Pathol       Date:  2010-03       Impact factor: 3.943

3.  Matrix metalloproteinase-9 secretion by human pituitary adenomas detected by cell immunoblot analysis.

Authors:  H Kawamoto; K Kawamoto; T Mizoue; T Uozumi; K Arita; K Kurisu
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

4.  The correlation of Ki-67 staining indices with tumour doubling times in regrowing non-functioning pituitary adenomas.

Authors:  S M Ekramullah; Y Saitoh; N Arita; T Ohnishi; T Hayakawa
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

5.  Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors : comparison between micro- and macroadenomas.

Authors:  M Losa; R L Barzaghi; P Mortini; A Franzin; F Mangili; M R Terreni; M Giovanelli
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

6.  Cyclins D1 and D3 and topoisomerase II alpha in inactive pituitary adenomas.

Authors:  W Saeger; S Schreiber; D K Lüdecke
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

7.  Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody.

Authors:  L Mastronardi; A Guiducci; C Spera; F Puzzilli; F Liberati; G Maira
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

8.  Analysis of the growth rate and cavernous sinus invasion of pituitary adenomas.

Authors:  H Kawamoto; T Uozumi; K Kawamoto; K Arita; T Yano; T Hirohata
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

Review 9.  Intracranial dissemination of pituitary adenoma. Case report and review of the literature.

Authors:  M T Giordana; P Cavalla; A Allegranza; B Pollo
Journal:  Ital J Neurol Sci       Date:  1994-05

10.  Clinical significance of Ki-67 labeling index in pituitary macroadenoma.

Authors:  Kyung-Il Paek; Seon-Hwan Kim; Shi-Hun Song; Seung-Won Choi; Hyeon-Song Koh; Jin-Young Youm; Youn Kim
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.